| Date Filed | Type | Description |
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 06/01/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 06/01/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 05/25/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/04/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 03/28/2023 |
8-K
| Quarterly results |
| 03/24/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/13/2023 |
4
| Eliya Yehuda (CFO) has filed a Form 4 on Raphael Pharmaceutical Inc.|
Txns:
| Granted 202,000 options to buy
@ $1.12, valued at
$226.2k
|
|
| 03/13/2023 |
4
| Pilo Shlomo (CEO) has filed a Form 4 on Raphael Pharmaceutical Inc.|
Txns:
| Granted 1,000,000 options to buy
@ $1.12, valued at
$1.1M
|
|
| 03/13/2023 |
4
| Press Joseph (Director) has filed a Form 4 on Raphael Pharmaceutical Inc.|
Txns:
| Granted 280,000 shares
@ $0
Granted 105,000 options to buy
@ $1.12, valued at
$117.6k
|
|
| 03/13/2023 |
4
| Louria Hayon Igal (Chief Technology Officer) has filed a Form 4 on Raphael Pharmaceutical Inc.|
Txns:
| Granted 999,000 options to buy
@ $0.01, valued at
$10k
|
|
| 03/13/2023 |
4
| Ofir Guy (CFO) has filed a Form 4 on Raphael Pharmaceutical Inc.|
Txns:
| Granted 1,000,000 shares
@ $0
Granted 1,000,000 options to buy
@ $1, valued at
$1M
|
|
| 01/26/2023 |
8-K/A
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 10/24/2022 |
8-K
| Quarterly results |
| 08/12/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 07/11/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 07/07/2022 |
8-K
| Changes in Registrant's Certifying Accountant, Departure of Directors or Certain Officers; Election of Directors; Appointment... |
| 06/28/2022 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 05/31/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 05/26/2022 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 05/16/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 03/30/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 01/19/2022 |
3
| Louria Hayon Igal (Chief Technology Officer) has filed a Form 3 on Raphael Pharmaceutical Inc. |
| 01/19/2022 |
3
| Eliya Yehuda (Director) has filed a Form 3 on Raphael Pharmaceutical Inc. |
| 01/19/2022 |
3
| Pilo Shlomo (CEO) has filed a Form 3 on Raphael Pharmaceutical Inc. |
| 01/19/2022 |
3
| Press Joseph (Director) has filed a Form 3 on Raphael Pharmaceutical Inc. |
| 12/02/2021 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 11/24/2021 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 11/19/2021 |
3
| Ofir Guy (CFO) has filed a Form 3 on Raphael Pharmaceutical Inc. |
| 11/16/2021 |
10-Q
| Quarterly Report for the period ended September 30, 2021 |
| 11/04/2021 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 09/23/2021 |
10-12G/A
| Form 10-12G/A - Registration of securities [Section 12(g)]: [Amend] |
| 09/02/2021 |
10-12G/A
| Form 10-12G/A - Registration of securities [Section 12(g)]: [Amend] |
|